Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.
Company profile
Ticker
COSM
Exchange
Website
CEO
Grigorios Siokas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cosmos Holdings Inc., PRIME ESTATES & DEVELOPMENTS INC
SEC CIK
Corporate docs
Subsidiaries
Cosmofarm Ltd. • SkyPharm, S.A. • Decahedron Ltd. ...
IRS number
270611758
COSM stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
424B3
Prospectus supplement
7 Mar 24
424B3
Prospectus supplement
29 Feb 24
424B3
Prospectus supplement
15 Feb 24
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
5 Feb 24
S-3
Shelf registration
29 Jan 24
8-K
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
22 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.14 mm | 1.60 mm | 1.51 mm | 2.24 mm |
Cash used (since last report) | n/a | n/a | 7.60 mm | 10.65 mm | 10.06 mm | 14.96 mm |
Cash remaining | n/a | n/a | -5.23 mm | -8.29 mm | -7.70 mm | -12.60 mm |
Runway (months of cash) | n/a | n/a | -4.6 | -5.2 | -5.1 | -5.6 |
Institutional ownership, Q2 2023
4.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 11 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.02 bn |
Total shares | 734.48 k |
Total puts | 0.00 |
Total calls | 400.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 291.91 k | $872.82 mm |
Geode Capital Management | 95.11 k | $284.38 mm |
Belvedere Trading | 89.38 k | $267.25 mm |
Simplex Trading | 57.45 k | $171.00 k |
Sabby Management | 35.01 k | $104.67 mm |
Group One Trading | 33.39 k | $99.82 mm |
Susquehanna International | 31.61 k | $94.51 mm |
BAC Bank Of America | 25.11 k | $75.06 mm |
STT State Street | 21.34 k | $63.82 mm |
NTRS Northern Trust | 20.55 k | $61.46 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Siokas Grigorios | Common Stock, par value $.001 | Buy | Acquire P | No | No | 0.8301 | 60,000 | 49.81 k | 1,394,597 |
22 Dec 23 | Anastasios Aslidis | Common Stock, $.001 par value | Sale back to company | Dispose D | No | No | 1.4632 | 200 | 292.64 | 20,000 |
24 Oct 23 | Georgios Terzis | Common Stock, $.001 par value | Grant | Acquire A | No | No | 1.01 | 51,485 | 52.00 k | 152,459 |
12 Oct 23 | Siokas Grigorios | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 23.66 | 6,712 | 158.81 k | 1,334,597 |
News
Cosmos Health Commences Development Of Cloudscreen 2.0, The New Iteration Of Its Next Generation AI Drug Repurposing Platform
21 Mar 24
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
22 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Feb 24
Cosmos Health Completes Acquisition of Cloudscreen AI Platform
23 Jan 24
Press releases
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
21 Mar 24
Cosmos Health Successfully Completes Acquisition of Pharmatrade's Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
29 Feb 24
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
21 Feb 24
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
21 Feb 24
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
20 Feb 24